Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis

Background & AimsThe latest Baveno VII consensus provided guidance for determining patients who have truly recompensated from hepatic decompensation. This study aimed to evaluate patients’ transplant-free survival in three different stages of cirrhosis.MethodsAll with chronic hepatitis B virus (HBV) infection and liver cirrhosis treated oral nucleos(t)ide analogues March 2006 December 2022 were identified a territory-wide database Hong Kong. Patients follow-up duration less than one year excluded. Subjects classified into mutually exclusive groups: 1. no decompensated events (i.e. compensated group); 2. occurred or 3. followed by recompensation according criteria group). A time-dependent Cox proportional hazard model was adopted evaluation. The period 5 years.Results4,701 cirrhotic HBV entecavir, tenofovir disoproxil fumarate (TDF) alafenamide (TAF) identified. During median [interquartile range 3.7, 5] years), 3,327 (70.8%), 1,347 (29.2%) 265 (5.6%) had compensated, decompensated, cirrhosis, respectively, at least once before the end study. In multivariable model, group similar compared (adjusted ratio [aHR] 1.16; 95% confidence interval [CI] 0.72-1.86; p =0.536). five-year rate 89.3% group, while it 76.0% reflecting minimal difference between two groups.ConclusionsThe clinical significance improving patient outcomes those suffering CHB highlighted this Early identification treatment might promote thus reduce mortality CHB.Impact ImplicationsThe introduces new concept recompensation, which refers reversal structural functional changes after removal, cure, suppression aetiology cirrhosis. It is essential investigate rates are able achieve as has significant implications medical resources required manage failure transplantation. features comparing do not. early use antiviral pivotal strategy potential significantly ultimately aid elimination hepatitis.